Skip to main content Back to Top
Advertisement

5/26/2016

Memantine Hydrochloride Extended-Release Capsules

Reason for the Shortage

    • Actavis states the reason for the shortage of Namenda XR capsules was manufacturing delay.
    • There are several other manufacturers of memantine immediate release tablets and these were not affected by the shortage.

Available Products

    • Namenda XR oral capsule, Actavis, 14 mg, 30 count, NDC 00456-3414-33
    • Namenda XR oral capsule, Actavis, 14 mg, 90 count, NDC 00456-3414-90
    • Namenda XR oral capsule, Actavis, 14 mg, unit-dose 100 count, NDC 00456-3414-63
    • Namenda XR oral capsule, Actavis, 21 mg, 30 count, NDC 00456-3421-33
    • Namenda XR oral capsule, Actavis, 28 mg, 30 count, NDC 00456-3428-33
    • Namenda XR oral capsule, Actavis, 28 mg, 90 count, NDC 00456-3428-90
    • Namenda XR oral capsule, Actavis, 28 mg, unit-dose 100 count, NDC 00456-3428-63
    • Namenda XR oral capsule, Actavis, 7 mg, 30 count, NDC 00456-3407-33
    • Namenda XR oral capsule, Actavis, Titration Pack 28 count, NDC 00456-3400-29

Estimated Resupply Dates

    • Actavis has all Namenda XR presentations available.

Updated

Updated May 26, 2016 by Leslie Jensen, PharmD, Drug Information Specialist. Created February 19, 2014 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins